Jean-François Balavoine

Author

Also Known As

BALAVOINE Francois, Balavoine François, Balavoine, François, F. Balavoine, Francois Balavoine, François Balavoine, Frédérique Jacquérioz Bausch, J F Balavoine, J. F. Balavoine, J.-F. Balavoine

Publications

987

Citations

H-Index

Concepts

All Affiliations

University Hospital of Geneva University of Geneva World Health Organization Johns Hopkins University Hôpital de la Tour

About

Jean-François Balavoine is an author at University Hospital of Geneva specializing in immunology, medicine, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	423
2	Immunology	6	6	423
3	Cell Biology	2	2	270
4	Cellular Physiology	1	1	206
5	Epidemiology	1	1	15

Jean-François Balavoine

Publications

812

Citations

H-Index

Page 1

	Year	Citations
Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). Jean-François Balavoine, B de Rochemonteix, Karen Williamson, Journal of Clinical Investigation ImmunologyPathologyCell ProliferationImmunotherapyLaf/il-1 Assay	1986	206
A urine inhibitor of interleukin 1 activity affects both interleukin 1 <i>alpha</i> and 1 <i>beta</i> but not tumor necrosis factor <i>alpha</i>. P Seckinger, Kate Williamson, Jean-François Balavoine, The Journal of Immunology	1987	140
Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021 Silvia Stringhini, María‐Eugenia Zaballa, Nick Pullen, Eurosurveillance	2021	70
Abolished in vitro antibody response in elderly: Exclusive involvement of prostaglandin-induced T suppressor cells Jean‐François Delfraissy, Pierre Galanaud, Christine Wallon, Clinical Immunology and Immunopathology InflammationAutoimmune DiseaseImmune RegulationImmunologyAutoimmunity	1982	64
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study María‐Eugenia Zaballa, Javier Perez‐Saez, Carlos de Mestral, The Lancet Regional Health - Europe	2022	59
Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance Javier Perez‐Saez, María‐Eugenia Zaballa, Sabine Yerly, Clinical Microbiology and Infection VaccinationAnti-sars-cov-2 AntibodiesViral PersistenceViral DiagnosticsVaccine Target	2021	51
Captopril and immune regulation Jean‐François Delfraissy, Pierre Galanaud, Jean-François Balavoine, Kidney International Autoimmune DiseasePathogenesisImmunologyImmune RegulationAutoimmunity	1984	47
Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland Silvia Stringhini, María-Eugenia Zaballa, Nick Pullen, Nature Communications	2021	46
Altered functions of peripheral blood monocytes in homosexual males and intravenous drug users with persistent generalized lymphadenopathy Pascale Roux‐Lombard, D. Aladjem, Jean-François Balavoine, European Journal of Clinical Investigation Normal MonocytesImmunodeficienciesImmunologyImmune SystemImmunotherapy	1986	40
Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland Hélène Baysson, Francesco Pennacchio, Ania Wisniak, BMJ Open	2022	39

Page 1